Abstract
Objectives: To elucidate whether the disease characteristics and prognosis of stageIV prostate cancer treated with primary androgen deprivation therapy differ between young and elderly patients. Methods: A total of 3006 patients identified from the database of the Japan Study Group of Prostate Cancer were included in the analysis according to the following entry criteria: age of 75 years or less and stageIV disease. These patients were stratified into three groups: young (aged ≤55 years); middle-aged (aged ≧56 and ≤65 years); and elderly (aged ≧66 and ≤75 years). Their prognoses were analyzed both within age groups and according to whether or not there was metastasis. Results: The proportion of lymph node metastasis was significantly higher in the young group than in the elderly group (P=0.007), and there were no significant differences in other factors among age groups. The overall survival rate at 5 years in the young group was significantly worse than that in the middle-aged and elderly groups (26.6%, 59.7% and 55.3%, respectively) in patients with stageIV disease with metastasis, although there was no difference among age groups in patients with stageIV disease without metastasis. Multivariate analysis showed that younger age was an independent strong prognostic factor in stageIV disease with metastasis. Conclusions: Young men with metastatic prostate cancer have a poor prognosis. Young age is an independent prognostic factor in stageIV metastatic prostate cancer patients treated with primary androgen deprivation therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 578-583 |
| Number of pages | 6 |
| Journal | International Journal of Urology |
| Volume | 21 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Primary androgen deprivation therapy
- Prostate cancer
- StageIV
- Young men
ASJC Scopus subject areas
- Urology
- Medicine(all)
Cite this
Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. / Kimura, Tomokazu; Onozawa, Mizuki; Miyazaki, Jun; Matsuoka, Taeko; Joraku, Akira; Kawai, Koji; Nishiyama, Hiroyuki; Hinotsu, Shiro; Akaza, Hideyuki.
In: International Journal of Urology, Vol. 21, No. 6, 2014, p. 578-583.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy
AU - Kimura, Tomokazu
AU - Onozawa, Mizuki
AU - Miyazaki, Jun
AU - Matsuoka, Taeko
AU - Joraku, Akira
AU - Kawai, Koji
AU - Nishiyama, Hiroyuki
AU - Hinotsu, Shiro
AU - Akaza, Hideyuki
PY - 2014
Y1 - 2014
N2 - Objectives: To elucidate whether the disease characteristics and prognosis of stageIV prostate cancer treated with primary androgen deprivation therapy differ between young and elderly patients. Methods: A total of 3006 patients identified from the database of the Japan Study Group of Prostate Cancer were included in the analysis according to the following entry criteria: age of 75 years or less and stageIV disease. These patients were stratified into three groups: young (aged ≤55 years); middle-aged (aged ≧56 and ≤65 years); and elderly (aged ≧66 and ≤75 years). Their prognoses were analyzed both within age groups and according to whether or not there was metastasis. Results: The proportion of lymph node metastasis was significantly higher in the young group than in the elderly group (P=0.007), and there were no significant differences in other factors among age groups. The overall survival rate at 5 years in the young group was significantly worse than that in the middle-aged and elderly groups (26.6%, 59.7% and 55.3%, respectively) in patients with stageIV disease with metastasis, although there was no difference among age groups in patients with stageIV disease without metastasis. Multivariate analysis showed that younger age was an independent strong prognostic factor in stageIV disease with metastasis. Conclusions: Young men with metastatic prostate cancer have a poor prognosis. Young age is an independent prognostic factor in stageIV metastatic prostate cancer patients treated with primary androgen deprivation therapy.
AB - Objectives: To elucidate whether the disease characteristics and prognosis of stageIV prostate cancer treated with primary androgen deprivation therapy differ between young and elderly patients. Methods: A total of 3006 patients identified from the database of the Japan Study Group of Prostate Cancer were included in the analysis according to the following entry criteria: age of 75 years or less and stageIV disease. These patients were stratified into three groups: young (aged ≤55 years); middle-aged (aged ≧56 and ≤65 years); and elderly (aged ≧66 and ≤75 years). Their prognoses were analyzed both within age groups and according to whether or not there was metastasis. Results: The proportion of lymph node metastasis was significantly higher in the young group than in the elderly group (P=0.007), and there were no significant differences in other factors among age groups. The overall survival rate at 5 years in the young group was significantly worse than that in the middle-aged and elderly groups (26.6%, 59.7% and 55.3%, respectively) in patients with stageIV disease with metastasis, although there was no difference among age groups in patients with stageIV disease without metastasis. Multivariate analysis showed that younger age was an independent strong prognostic factor in stageIV disease with metastasis. Conclusions: Young men with metastatic prostate cancer have a poor prognosis. Young age is an independent prognostic factor in stageIV metastatic prostate cancer patients treated with primary androgen deprivation therapy.
KW - Primary androgen deprivation therapy
KW - Prostate cancer
KW - StageIV
KW - Young men
UR - http://www.scopus.com/inward/record.url?scp=84901691020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901691020&partnerID=8YFLogxK
U2 - 10.1111/iju.12389
DO - 10.1111/iju.12389
M3 - Article
C2 - 24405474
AN - SCOPUS:84901691020
VL - 21
SP - 578
EP - 583
JO - International Journal of Urology
JF - International Journal of Urology
SN - 0919-8172
IS - 6
ER -